BridgeBio Pharma (BBIO) News Today $34.85 +0.94 (+2.77%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period F M Investments LLC Makes New $2.67 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)F M Investments LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 97,198 shares of the company's stock, valued atApril 13 at 6:17 AM | marketbeat.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comFernwood Investment Management LLC Raises Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Fernwood Investment Management LLC increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 6.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 278,330 shares of the company's stock afterApril 11, 2025 | marketbeat.comRaymond James Financial Inc. Takes $456,000 Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Raymond James Financial Inc. purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 16,631 shares of the comApril 10, 2025 | marketbeat.comBridgeBio management to meet with Piper SandlerApril 9, 2025 | markets.businessinsider.comSchroder Investment Management Group Acquires New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Schroder Investment Management Group bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 34,741 shares of the company's stock, vApril 9, 2025 | marketbeat.comNorges Bank Invests $29.24 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Norges Bank purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,065,479 shares of the company's stock, valued at approximately $29,237,000. NorgApril 8, 2025 | marketbeat.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Sells 30,000 Shares of StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 30,000 shares of the firm's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total transaction of $1,021,500.00. Following the completion of the transaction, the director now owns 12,000 shares in the company, valued at $408,600. The trade was a 71.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.April 5, 2025 | marketbeat.comCinctive Capital Management LP Invests $3.13 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Cinctive Capital Management LP bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 114,202 shares of the company's stock, valued at approximately $3,13April 5, 2025 | marketbeat.comAlliancebernstein L.P. Sells 33,374 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Alliancebernstein L.P. lessened its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,794,292 shares of the company's stock after sellingApril 5, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis Sells 30,000 SharesApril 4, 2025 | insidertrades.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Holdings Raised by Vanguard Group Inc.Vanguard Group Inc. increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 6.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,077,915 shares of the company's stock after purcApril 4, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - Time to Sell?BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - Should You Sell?April 3, 2025 | marketbeat.comKLP Kapitalforvaltning AS Makes New $692,000 Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)KLP Kapitalforvaltning AS bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,235 shares of the company's stock, valued at approximatelyApril 3, 2025 | marketbeat.comBridgeBio Pharma Target of Unusually High Options Trading (NASDAQ:BBIO)BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) was the target of some unusual options trading on Monday. Investors purchased 8,235 call options on the stock. This represents an increase of approximately 88% compared to the typical volume of 4,371 call options.April 1, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from Analysts at Redburn AtlanticRedburn Atlantic began coverage on shares of BridgeBio Pharma in a research report on Monday. They set a "buy" rating and a $50.00 price objective on the stock.April 1, 2025 | marketbeat.comBridgeBio reports pre-specified subgroup analysis of ATTRibute-CM trialMarch 31, 2025 | markets.businessinsider.comRedburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy RecommendationMarch 31, 2025 | msn.comBridgeBio initiated with a Buy at Redburn AtlanticMarch 31, 2025 | markets.businessinsider.comAcoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CMMarch 31, 2025 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Pictet Asset Management Holding SAPictet Asset Management Holding SA lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 35.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,807,472 shares of the company's stock after selling 99March 31, 2025 | marketbeat.comWhy BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to BuyMarch 30, 2025 | msn.comAmerican Century Companies Inc. Raises Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)American Century Companies Inc. grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 9.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,015,728 shares of the company's stock after purchasing an additionMarch 30, 2025 | marketbeat.comTeacher Retirement System of Texas Has $994,000 Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Teacher Retirement System of Texas raised its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 28.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,208 shares of the company'March 30, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by NEOS Investment Management LLCNEOS Investment Management LLC increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 26.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141March 29, 2025 | marketbeat.comBridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone PaymentMarch 29, 2025 | nasdaq.comNeil Kumar Sells 75,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 75,000 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $36.87, for a total value of $2,765,250.00. Following the completion of the transaction, the chief executive officer now owns 4,948,447 shares in the company, valued at approximately $182,449,240.89. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.March 28, 2025 | marketbeat.comBIT Capital GmbH Grows Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)BIT Capital GmbH boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 23.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 274,915 shares of the company's stock after buyingMarch 28, 2025 | marketbeat.comJapan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease DrugMarch 27, 2025 | benzinga.comBridgeBio announces Japanese MHLW approved acoramidis for treating ATTR-CMMarch 27, 2025 | markets.businessinsider.comBeyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CMMarch 27, 2025 | globenewswire.comBridgeBio Pharma (NASDAQ:BBIO) Trading 8.9% Higher After Analyst UpgradeBridgeBio Pharma (NASDAQ:BBIO) Trading Up 8.9% on Analyst UpgradeMarch 25, 2025 | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) StockJPMorgan Chase & Co. upped their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday.March 25, 2025 | marketbeat.com13,155 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Cibc World Markets CorpCibc World Markets Corp purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 13,155 shares of the company's stock, valued at approximaMarch 25, 2025 | marketbeat.comBridgeBio price target raised to $50 from $44 at JPMorganMarch 24, 2025 | markets.businessinsider.comBridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific SessionsMarch 24, 2025 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Emerald Advisers LLCEmerald Advisers LLC raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 4.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,150,868 shares of the company's stock after purchaMarch 24, 2025 | marketbeat.comSwiss National Bank Grows Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Swiss National Bank increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 9.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 240,300 shares of the company's stock after buying an additMarch 23, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Intech Investment Management LLCIntech Investment Management LLC increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 47.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,647 shares of the company's stock aftMarch 22, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and ten have assigneMarch 22, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)March 21, 2025 | markets.businessinsider.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | globenewswire.comBiggest stock movers Friday: NIO, ALNY, FDX, and moreMarch 21, 2025 | msn.comPrimecap Management Co. CA Buys 8,776 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Primecap Management Co. CA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 915,500 shares of the company's stock after acquiring an additional 8,776 sharMarch 21, 2025 | marketbeat.comKazazian Asset Management LLC Makes New Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Kazazian Asset Management LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 13,520 shares of the company's stock, valued at approximately $371,000. Other instituMarch 20, 2025 | marketbeat.comRoyce & Associates LP Purchases 22,833 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Royce & Associates LP increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 18.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 144,788 shares of the company's stock after acquiringMarch 20, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - What's Next?BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - Here's What HappenedMarch 19, 2025 | marketbeat.comBridgeBio Pharma, Inc.: BridgeBio Announces CFO SuccessionMarch 18, 2025 | finanznachrichten.deBridgeBio CFO Brian Stephenson to depart, Thomas Trimarchi succeedsMarch 18, 2025 | markets.businessinsider.comSkandinaviska Enskilda Banken AB publ Has $1.13 Million Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Skandinaviska Enskilda Banken AB publ boosted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,514 shares of the company's stock after buyiMarch 18, 2025 | marketbeat.com Remove Ads Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼1.300.80▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼88▲BBIO Articles Average Week Remove Ads Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beigene News BioNTech News Teva Pharmaceutical Industries News Intra-Cellular Therapies News Summit Therapeutics News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Viatris News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
